Masahiro Toide

Tokyo Metropolitan Komagome Hospital

Papers

15

Total Citations

81

H-Index

5

About

Masahiro Toide is a leading urological surgeon and researcher whose work centers on improving outcomes for prostate cancer patients undergoing robot-assisted radical prostatectomy (RARP). As a key member of the MSUG94 group, Toide has spearheaded large-scale, multicenter retrospective cohort studies across Japan that have reshaped clinical decision-making in robotic surgery. His most impactful contribution challenges the routine use of pelvic lymphadenectomy, demonstrating that it may not improve biochemical recurrence-free survival—a finding with direct implications for reducing surgical morbidity. Toide has also developed predictive nomograms for lymph node involvement and identified prognostic factors such as positive surgical margin locations, lymphovascular invasion, and inflammation-related parameters. With over 70 citations across his top papers, his work provides critical evidence on oncological outcomes, complication risks like inguinal hernia, and the influence of hospital volume on surgical quality. By systematically analyzing the nuances of Grade Group 4 subgroups and seminal vesicle invasion, Toide continues to refine risk stratification and personalize treatment for prostate cancer patients in the robotic surgery era.

Research Focus

Key Achievements

5
H-Index
15
Papers
81
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group)
15 citations · 2022
📈 Most Prolific Year: 2023 (6 Papers)
🤝 Key Collaborators: 26
🏛 Institutions: Tokyo Metropolitan Komagome Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago